Results 241 to 250 of about 18,195 (260)
Some of the next articles are maybe not open access.
Crystal structure of lansoprazole sulfone
Journal of Structural Chemistry, 2007The structure of 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl} sulfonyl)-1H-1,3-benzimidazole, C16H14N3O3F3S, has been solved. The compound belongs to the monoclinic space group (P21/c) with cell parameters a = 8.8693(9) A, b = 23.369(2) A, c = 8.6141(8) A, β = 104.68(1)°, V = 1727.2(3) A3, Z = 4.
K. Ravikumar, G. Y. S. K. Swamy
openaire +2 more sources
Pharmacokinetic Interaction Between Acetaminophen and Lansoprazole
Journal of Clinical Gastroenterology, 1999Because of its minimal gastric toxicity, acetaminophen is the analgesic of choice for patients with gastric acid-related disorders. Because proton pump inhibitors are widely used, concomitant prescription of acetaminophen and lansoprazole would be prevalent. This crossover study was conducted to investigate an acetaminophen-lansoprazole interaction. On
Iiku Enatsu +8 more
openaire +2 more sources
Lansoprazole for Maintenance of Remission of Erosive Oesophagitis
Drugs, 2002Gastro-oesophageal reflux disease, which is experienced daily by a significant proportion of individuals, may result in serious sequelae such as erosive oesophagitis. Short-term treatment with acid antisecretory therapy (a proton pump inhibitor or a histamine H(2) receptor antagonist) is highly effective in healing the erosive oesophagitis lesion ...
Bidan Huang +3 more
openaire +3 more sources
Delayed-Release Lansoprazole plus Naproxen
Drugs, 2004A combination package containing delayed-release capsules of the proton pump inhibitor lansoprazole (15 mg once daily) and tablets of the NSAID naproxen (375 or 500 mg twice daily) has been approved for reducing the risk of NSAID-associated gastric ulcers in NSAID-requiring patients with a documented history of gastric ulcer.
Keri Wellington, Monique P Curran
openaire +3 more sources
Eradication of Helicobacter pylori with lansoprazole and clarithromycin
Alimentary Pharmacology & Therapeutics, 1995SUMMARY Background: Helicobacter pylori eradication with omeprazole and clarithromycin varies between 40 and 80%. The dose, frequency and duration of treatment may account for these differences. Lansoprazole, a recently introduced proton pump inhibitor, is a more potent H. pylori bacteriostat in vitro than omeprazole. The aim of this open, comparative,
J. J. Misiewicz +5 more
openaire +3 more sources
Efficacy of Lansoprazole in Eradication of Helicobacter pylori
Journal of Clinical Gastroenterology, 1995Fifty-eight Helicobacter pylori-positive ulcer patients received omeprazole 20 mg (n = 15), or lansoprazole 30 mg (n = 23), lansoprazole 60 mg (n = 13), or E3810 20 mg (n = 7) q.d. Another 63 H. pylori-positive ulcer patients received lansoprazole and clarithromycin for 2 weeks. Patients received lansoprazole 30 mg and clarithromycin 400 mg (group 1, n
Yushi Taniguchi +7 more
openaire +3 more sources
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses
Expert Opinion on Pharmacotherapy, 2001Lansoprazole (Prevacid, TAP Pharmaceuticals, Inc.) is a substituted benzimidazole that inhibits gastric acid secretion. This agent is approved for the short-term treatment of erosive reflux oesophagitis, active gastric ulcer, active duodenal ulcer and the treatment of non-steroidal anti-inflammatory drug (NSAID)-induced gastric and duodenal ulcers.
openaire +3 more sources
Lansoprazole and Helicobacter pylori infection.
Clinical therapeutics, 1993Helicobacter pylori-associated gastritis is present in virtually all patients with duodenal ulcer (DU). Eradication of H pylori is associated with a highly significant decline in the recurrence rates of DU, indicating that treatments aimed at eradicating H pylori are mandatory in these patients.
PALLONE F +7 more
openaire +2 more sources
Patent expiration for lansoprazole
American Journal of Health-System Pharmacy, 2004Lee C. Vermeulen +2 more
openaire +2 more sources